Treatment of Splenic Marginal Zone Lymphoma with Hepatitis C Virus Infection

In SMZL patients with concurrent HCV infection, anti-viral therapy is a critical first consideration. Management of the viral infection is addressed up front, before or alongside lymphoma-directed treatment decisions.

For symptomatic disease, systemic therapy is the basis of management, with options that span immunotherapy-based and combined regimens. Additional interventional approaches are considered in selected patients depending on clinical presentation and fitness. Which approach is appropriate — and in what context — is determined by a structured algorithm that accounts for several patient and disease variables. The full protocol provides this detail.

Response is assessed against defined haematological and imaging endpoints: resolution of splenomegaly, recovery of blood counts to specified thresholds, and clearance of disease in peripheral blood and bone marrow.